What question did this study set out to answer?

The aim is to review the mechanisms and biomarkers associated with therapeutic drugs for metabolic-associated steatotic liver disease (MASLD).

April 27, 2026Frontiers in Cell and Developmental BiologyOpen Access

Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease

View Full Paper

Ask AI

Bookmark

Authors

LXLifen XueThe Affiliated Yongchuan Hospital of Chongqing Medical University XWXin WangNaval Medical Research Command JMJingxin MaoSouthwest University

Discussion

Member takes

Implication

Review explores mechanistic pathways and biomarkers for metabolic-associated steatotic liver disease, suggesting implications for diagnosis and treatment.

Key Points

The aim is to review the mechanisms and biomarkers associated with therapeutic drugs for metabolic-associated steatotic liver disease (MASLD).
Systematically collated literature on mechanistic pathways and biomarkers for MASLD.
Analyzed mechanisms of action and signaling pathways of therapeutic drugs.
Evaluated characteristics of various biomarkers related to MASLD.
Drugs for MASLD treatment regulate lipid metabolism and ameliorate insulin resistance, reducing inflammation and oxidative stress.
PPAR agonists improve lipid metabolism and insulin resistance via the PPAR signaling pathway.
Key biomarkers include metabolomic, inflammatory, liver fibrosis, and non-coding RNA, each with distinct diagnostic values.

Cite This Study

Xue et al. (2026) studied this question.

synapsesocial.com/papers/69eefc23fede9185760d357e https://doi.org/10.3389/fcell.2026.1808135

View Full Paper

Ask AI

Bookmark

Implication

Review explores mechanistic pathways and biomarkers for metabolic-associated steatotic liver disease, suggesting implications for diagnosis and treatment.

Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider